JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

165.57 -0.4

Visão Geral

Variação de preço das ações

24h

Atual

Mín

164.7

Máximo

166.47

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+19.01% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

508M

8.4B

Abertura anterior

165.97

Fecho anterior

165.57

Sentimento de Notícias

By Acuity

75%

25%

322 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de mai. de 2026, 23:47 UTC

Ganhos

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3 de mai. de 2026, 22:35 UTC

Ganhos

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3 de mai. de 2026, 23:32 UTC

Ganhos

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3 de mai. de 2026, 23:20 UTC

Conversa de Mercado

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3 de mai. de 2026, 23:16 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3 de mai. de 2026, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

3 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3 de mai. de 2026, 22:20 UTC

Ganhos

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3 de mai. de 2026, 22:08 UTC

Ganhos

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3 de mai. de 2026, 22:05 UTC

Ganhos

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3 de mai. de 2026, 22:05 UTC

Ganhos

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3 de mai. de 2026, 22:05 UTC

Ganhos

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3 de mai. de 2026, 22:04 UTC

Ganhos

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3 de mai. de 2026, 22:03 UTC

Ganhos

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3 de mai. de 2026, 22:03 UTC

Ganhos

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3 de mai. de 2026, 22:02 UTC

Ganhos

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3 de mai. de 2026, 22:02 UTC

Ganhos

NAB 1H Cash Earnings A$2.64B>NAB.AU

3 de mai. de 2026, 22:02 UTC

Ganhos

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3 de mai. de 2026, 22:01 UTC

Ganhos

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3 de mai. de 2026, 22:01 UTC

Ganhos

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3 de mai. de 2026, 22:01 UTC

Ganhos

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3 de mai. de 2026, 15:06 UTC

Ganhos

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

19.01% parte superior

Previsão para 12 meses

Média 197.3 USD  19.01%

Máximo 235 USD

Mínimo 160 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

322 / 347 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat